Hologic, Inc. $HOLX Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 451,581 shares of the medical equipment provider’s stock after acquiring an additional 21,369 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.20% of Hologic worth $30,477,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in HOLX. Winnow Wealth LLC bought a new stake in shares of Hologic in the 3rd quarter worth about $26,000. Root Financial Partners LLC acquired a new position in Hologic in the third quarter worth about $27,000. SJS Investment Consulting Inc. increased its holdings in Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares during the last quarter. Loomis Sayles & Co. L P bought a new stake in Hologic in the second quarter valued at about $33,000. Finally, Smartleaf Asset Management LLC raised its stake in Hologic by 168.5% during the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 310 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Finally, Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and decreased their price target for the company from $79.00 to $78.00 in a report on Monday, January 5th. Two investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $78.42.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $75.36 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The firm has a market capitalization of $16.82 billion, a PE ratio of 31.40, a P/E/G ratio of 2.24 and a beta of 0.72. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.49. The business’s fifty day moving average price is $74.95 and its two-hundred day moving average price is $72.16.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the firm posted $0.87 EPS. The business’s revenue was up 2.5% compared to the same quarter last year. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.